

Exposure to welding fumes and lower airway infection with *Streptococcus pneumoniae*



Reetika Suri, PhD,^a Jimstan Periselneris, MB BS,^b Sophie Lanone, PhD,^c Patti C. Zeidler-Erdely, PhD,^d Geoffrey Melton, BSc,^e Keith T. Palmer, MD,^f Pascal Andujar, MD,^c James M. Antonini, PhD,^d Vanessa Cohignac, MSc,^c Aaron Erdely, PhD,^d Ricardo J. Jose, MB BS,^b Ian Mudway, PhD,^g Jeremy Brown, MD,^b and Jonathan Grigg, MD^a
London, Cambridge, and Southampton, United Kingdom, Créteil, France, and Morgantown, WV

Background: Welders are at increased risk of pneumococcal pneumonia. The mechanism for this association is not known. The capacity of pneumococci to adhere to and infect lower airway cells is mediated by host-expressed platelet-activating factor receptor (PAFR).

Objective: We sought to assess the effect of mild steel welding fumes (MS-WF) on PAFR-dependent pneumococcal adhesion and infection to human airway cells *in vitro* and on pneumococcal airway infection in a mouse model.

Methods: The oxidative potential of MS-WF was assessed by their capacity to reduce antioxidants *in vitro*. Pneumococcal adhesion and infection of A549, BEAS-2B, and primary human bronchial airway cells were assessed by means of quantitative bacterial culture and expressed as colony-forming units (CFU). After intranasal instillation of MS-WF, mice were infected with *Streptococcus pneumoniae*, and bronchoalveolar lavage fluid (BALF) and lung CFU values were determined. PAFR protein levels were assessed by using immunofluorescence and immunohistochemistry, and PAFR mRNA expression was assessed by using quantitative PCR. PAFR was blocked by CV-3988, and oxidative stress was attenuated by N-acetylcysteine. **Results:** MS-WF exhibited high oxidative potential. In A549 and BEAS-2B cells MS-WF increased pneumococcal adhesion and infection and PAFR protein expression. Both CV-3988 and N-acetylcysteine reduced MS-WF-stimulated pneumococcal adhesion and infection of airway cells. MS-WF increased mouse lung PAFR mRNA expression and increased BALF and lung

pneumococcal CFU values. In MS-WF-exposed mice CV-3988 reduced BALF CFU values.

Conclusions: Hypersusceptibility of welders to pneumococcal pneumonia is in part mediated by the capacity of welding fumes to increase PAFR-dependent pneumococcal adhesion and infection of lower airway cells. (*J Allergy Clin Immunol* 2016;137:527-34.)

Key words: Occupational disease, welding fumes, platelet-activating factor receptor, *Streptococcus pneumoniae*, pneumonia, bacterial adhesion and infection

Occupational data from England and Wales for 1970 to 1972 report there were 66 deaths among welders compared with 42 expected deaths.¹ Similar data for 1990 to 2000 suggest that excess deaths among welders are due to pneumonias other than broncho-pneumonia, principally lobar pneumonia, and are present in other occupations associated with exposure to metal fumes.² Hypersusceptibility to pneumonia appears to be reversible because excess deaths are limited to welders of less than the normal retirement age,² and a recent United Kingdom (UK) case-control study found that hospital admissions for community-acquired pneumococcal pneumonia in working-age men were associated with occupational exposure to metal fumes in the past year but not in earlier periods.³ Increased risk of pneumonia in welders has also been found outside the UK. For example, in a cohort of more than 30,000 Swedish construction workers with exposure to metal fumes, Toren et al⁴ reported that mortality from lobar pneumonia was 3.7-fold higher and mortality from pneumococcal pneumonia was 5.8-fold higher relative to their peers. By contrast, deaths from pneumonia in retired metal workers were only marginally increased.⁴ Although these findings suggest that inhalation of welding fumes (WF) increases the risk of pneumococcal infection, the high prevalence of other exposures in welders associated with increased risk of pneumococcal disease, such as smoking,^{5,6} and the lack of a biologically plausible mechanism result in uncertainties about causality. However, animal studies reporting that WF impair pulmonary clearance of *Listeria monocytogenes*⁷⁻⁹ suggest that WF have the potential to adversely affect the pulmonary innate immune system.

Adherence of pneumococci to lower airway cells is a first step in the development of airway infection leading to pneumonia.¹⁰ For *Streptococcus pneumoniae* (and other phosphorylcholine-expressing bacteria, such as nontypeable *Haemophilus influenzae*¹¹ and *Acinetobacter* species¹²), adhesion and infection of lower airway cells is facilitated by an interaction between bacterial phosphorylcholine and the platelet-activating factor receptor (PAFR; 10-alkyl-2-acetyl-glycerophosphocholine PAF) expressed on host cells.¹³ Because previous studies report that inhaled toxins,

From ^athe Blizzard Institute, Queen Mary University of London; ^bthe Centre for Inflammation and Tissue Repair, Department of Medicine, Royal Free and University College Medical School, Rayne Institute, London; ^cInserm U955 Équipe 4, Faculté de Médecine, Créteil; ^dthe Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown; ^ethe Welding Institute, Cambridge; ^fthe MRC Lifecourse Epidemiology Unit, University of Southampton; and ^gthe MRC-PHE Centre for Environment and Health, Analytical & Environmental Sciences Division, Faculty of Life Sciences & Medicine, King's College London.

Supported by Colt Foundation grant number CF/05/12. R.J.J. is supported by Wellcome Trust grant 097216/Z/11/Z, and J.P. is supported by Medical Research Council grant MR/K00168X/1.

Disclosure of potential conflict of interest: G. Melton is exclusively funded by the Welding Institute (an independent research organization, limited by guarantee), which is funded by member subscriptions (about 800 members worldwide), single-client and joint industry projects, and European Union- and United Kingdom-funded projects. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication February 11, 2015; revised May 29, 2015; accepted for publication June 29, 2015.

Available online August 12, 2015.

Corresponding author: Jonathan Grigg, MD, Blizzard Institute, London E1 2AT, United Kingdom. E-mail: j.grigg@qmul.ac.uk.

The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections

0091-6749/\$36.00

© 2015 American Academy of Allergy, Asthma & Immunology

<http://dx.doi.org/10.1016/j.jaci.2015.06.033>

Abbreviations used

BALF:	Bronchoalveolar lavage fluid
CFU:	Colony-forming units
IPD:	Invasive pneumococcal disease
LDH:	Lactate dehydrogenase
MS-WF:	Mild steel welding fumes
NAC:	N-acetylcysteine
OP:	Oxidative potential
PAFR:	Platelet-activating factor receptor
PM:	Particulate matter
StS-WF:	Stainless steel welding fumes
UK:	United Kingdom
WF:	Welding fumes

including fossil fuel–derived particulate matter (PM) and cigarette smoke,^{14,15} through induction of oxidative stress, upregulate PAFR-dependent adhesion of pneumococci to airway epithelial cells, we hypothesized that hypersusceptibility to pneumonia in welders is mediated through PAFR-dependent pneumococcal adhesion. Therefore in this study we sought to assess the oxidative potential (OP) of mild steel welding fumes (MS-WF), the effect of MS-WF on PAFR-dependent pneumococcal adhesion and infection in human lower airway cells *in vitro*, and PAFR-dependent pneumococcal airway infection in a mouse model. We also assessed PAFR in stored lung tissue from a study in which mice were exposed to aerosolized stainless steel welding fumes (StS-WF) and from a study of particles in welders' lungs.¹⁶

METHODS**WF: Generation and composition**

MS-WF were a gift from the Welding Institute (Cambridge, UK). MS-WF were obtained by using a standardized method in accordance with the International Standard 15011-1:2009, as previously described.¹⁷ Briefly, manual metal arc welding electrodes (mild steel E7018 basic type) were run to produce a weld bead inside a fume collection system. MS-WF with a mode particle diameter of 6.8 μm ¹⁸ were extracted through the hood on top of the box, collected on a filter paper, removed by brushing, and stored in airtight glass containers. The composition of MS-WF was determined after digestion in nitric/hydrochloric acid in a high-temperature, closed-vessel, microwave-assisted dissolution system. Analysis was done by using inductively coupled plasma–atomic emission spectroscopy. Before use, MS-WF were suspended in PBS.

WF: OP

The OP of MS-WF was determined based on their ability to oxidize antioxidants from a validated *in vitro* respiratory tract lining fluid model containing equimolar (200 $\mu\text{mol/L}$) and physiologically relevant concentrations of ascorbate, urate, and glutathione.¹⁹ Incubations were performed with particle suspensions at a final concentration of 50 $\mu\text{g/mL}$ for 4 hours at 37°C (pH 7.4) in parallel to particle-free and PM controls (an oxidatively inert carbon black [M120] and an oxidatively active urban PM [NIST1648a]). At the end of this period, particles were removed by means of centrifugation (13,000 rpm at 4°C), and samples were acidified with metaphosphoric acid (final concentration 5%) before determination of the remaining antioxidant concentrations by using reverse-phase HPLC with electrochemical detection (for ascorbate) and the glutathione disulphide-reductase-5, 5'-dithio-bis (2-nitrobenzoic acid) recycling assay (for glutathione).¹⁹ OP was determined based on the percentage loss of ascorbate and glutathione over the 4-hour incubation period relative to a 4-hour particle-free control (reflecting background auto-oxidation rates). Under these conditions, urate losses are not significant.^{16,17} The percentage loss of ascorbate and glutathione over the 4-hour incubation was then normalized to the particle concentration used in

the respiratory tract lining fluid assay (50 $\mu\text{g/mL}$) to generate 2 separate measures of OP: glutathione-dependent OP ($\text{OP}^{\text{glutathione}}$) per microgram and ascorbate-dependent OP ($\text{OP}^{\text{ascorbate}}$) per microgram. In addition, an aggregate sum of the 2 measures was calculated (OP^{total} per microgram),²⁰ previous work having shown that ascorbate and glutathione oxidation is sensitive to different panels of oxidants.^{16,17}

Pneumococcal adhesion and infection: Human airway cells

A549 cells, a type II pneumocyte cell line (Sigma-Aldrich, Poole, UK), were maintained in Dulbecco modified Eagle medium supplemented with FBS, L-glutamine, and antibiotics (Lonza, Basel, Switzerland). Passage number was less than 20. BEAS-2B, a bronchial epithelial cell line, was a gift from Dr Nicolas Mercardo (National Heart and Lung Institute, Imperial College London, London, UK). BEAS-2B cells were maintained in RPMI-1640 medium containing HEPES (Life Technologies, Warrington, UK) supplemented with FBS L-glutamine and antibiotics. Passage number was less than 20.

Cell viability was assessed by using the lactate dehydrogenase (LDH) assay (Sigma-Aldrich), according to the manufacturer's instructions. Cells treated with distilled water (indicating 100% LDH release) were used as a positive control. Primary human bronchial epithelial cells (purchased from Promocell, Heidelberg, Germany; lot no. 4032402) were maintained according to the manufacturer's instructions. Passage number was less than 4. The type 2 *S pneumoniae* encapsulated strain D39 was purchased from the National Collection of Type Cultures (NCTC 7466; Central Public Health Laboratory, London, UK) and grown in liquid culture brain-heart infusion broth (Oxoid, Basingstoke, UK) to the midlogarithmic phase ($\text{OD}_{600} = 0.4\text{--}0.6$) before use.

Pneumococcal adhesion and infection, and infection alone of airway cells were assessed by using a standard *in vitro* assay.^{14,15} Briefly, airway epithelial cells were cultured with MS-WF for 2 hours, washed, and infected with *S pneumoniae* at a multiplicity of infection of 100 for 2 hours to assess the combination of pneumococcal adhesion and infection of cells. Cells were then vigorously washed, detached, and lysed with sterile distilled water. Serial dilutions of the samples were plated on brain-heart infusion agar containing 5% horse blood (Oxoid), and colony-forming units (CFU) per milliliter were assessed. In this assay CFU values after cell lysis reflect both pneumococci attached to the surfaces of airway cells (ie, the adherent fraction) and pneumococci that penetrate into cells (ie, the infective fraction). The adherent fraction was first killed with gentamicin (200 mg/mL) and penicillin G (10 mg/mL), to assess the infective fraction alone. Intracellular pneumococci that were protected from antibiotics were recovered by means of cell lysis with ice-cold sterile water, and CFU values were determined.¹⁵ The functional role of PAFR was assessed by adding a specific PAFR blocker, (RS)-2-methoxy-3-(octadecylcarbamoyloxy)-propyl-2-(3-thiazolo) ethylphosphate (CV-3988),²¹ at a final concentration of 20 $\mu\text{mol/L}$. The role of oxidative stress was assessed by adding the thiol antioxidant N-acetylcysteine (NAC; Sigma-Aldrich)²² at a final concentration of 5 mmol/L at the same time as MS-WF.

Pneumococcal infection: Mouse model

Four- to 6-week-old female CD1 mice (Charles River, Welwyn Garden City, UK) were exposed to MS-WF in 50 μL of PBS (administered either as a single 600- μg dose or as divided doses) through intranasal installation after achievement of isoflurane anesthesia. Twenty-four hours after instillation of MS-WF, animals were intranasally infected with 5×10^6 *S pneumoniae* strain D39 in 50 μL of PBS. Animals were killed at 24 hours after pneumococcal infection by using a pentobarbital overdose. Pneumococcal CFU values in bronchoalveolar lavage fluid (BALF), lung tissue (done after BAL), and blood were assessed by plating serial dilutions on brain-heart infusion agar containing 5% horse blood (Oxoid). Mouse experiments were approved by University College London's Biological Services Ethical Committee under UK Home Office Project License PPL70/6510 and performed according to UK national guidelines for animal use and care under UK Home Office license in accordance with European Union Directive 2010/63/EU. Animals received 30 μL of 5 mg/kg of the PAFR blocker CV-3988 (Sigma-Aldrich) administered by means of tail vein injection 1 hour before pneumococcal infection to assess the effect of blocking PAFR.

PAFR expression: Human airway cells

Expression of PAFR protein by airway cells *in vitro* was quantified by means of fluorescence microscopy. Briefly, 4×10^5 cells were grown on coverslips in 24-well plates and cultured with MS-WF. Cells were fixed in ice-cold 4% paraformaldehyde for 10 minutes at room temperature and washed with PBS with 10% FCS (wash buffer). Cells were exposed overnight at 4°C to either a mouse anti-human PAFR IgG_{2a} antibody (1:100, CAY160600; Cayman Chemicals, Ann Arbor, Mich) or a mouse IgG isotype control (Bio-Legend, San Diego, Calif). Cells were washed with wash buffer and an Alexa Fluor 488–conjugated goat anti-mouse antibody applied (1:1000; Invitrogen, Grand Island, NY) at room temperature for 30 minutes under aluminum foil. Cells were washed with wash buffer and 4', 6-Diamidino-2-Phenylindole, Di-lactate (1:1000, Invitrogen) applied at room temperature for 15 minutes under aluminum foil. Finally, cells were washed with wash buffer, and the coverslips were mounted on glass slides and sealed. Slides were left to air dry under foil for 4 hours and stored overnight at 4°C for analysis. Images were taken with an epifluorescence microscope and analyzed by using ImageJ software (National Institutes of Health, Bethesda, Md). The isotype control confirmed that interactions between the anti-human PAFR antibody and the secondary antibody detected by using immunofluorescence microscopy were specific. Images were obtained from 3 randomly selected areas of each slide and analyzed blind to exposure status. By using the software, a fluorescence intensity threshold was set to discount background nonspecific fluorescence. The area of specific fluorescence was then measured for each image, with 1 to 3 images analyzed in each experiment and expressed as square micrometers.

PAFR mRNA expression: Mouse model

Expression of mouse lung PAFR mRNA was assessed by means of quantitative PCR. Briefly, lungs were removed and stored in RNAlater (Qiagen, Manchester, UK) at –80°C. RNA was extracted with the RNeasy Kit (Qiagen). First-strand cDNA synthesis was carried out with SuperScript VILO MasterMix (Life Technologies). Real-time PCR was carried out with TaqMan Gene Expression MasterMix (Life Technologies). mRNA analysis was carried out according to the manufacturer's instructions by using relative quantification involving normalization to a reference gene. Primer/probe sets used were as follows: mouse reference gene β_2 -microglobulin, Mm00437762_m1; mouse PAFR, Mm02621061_m1 (Life Technologies). All primer/probe sets spanned exon-exon boundaries to control for genomic DNA contamination.

PAFR: Stored samples

The effect of aerosolized WF on mouse lung PAFR mRNA expression was assessed by using tissue samples from mice exposed to aerosolized StS-WF. Mouse lung tissue was obtained from 6-week-old C57BL/6J mice (Jackson Laboratory, Bar Harbor, Me) exposed by means of whole-body inhalation to 40 mg/m³ StS-WF for 3 hours per day for up to 10 days. Lung PAFR mRNA expression was compared between air-exposed and StS-WF-exposed controls at both 4 hours and 28 days after the last dose. The design and construction of the aerosol generator and the characterization of StS-WF have been previously described.²³ Full details are provided in the [Methods](#) section in this article's Online Repository at www.jacionline.org.

The distribution of airway PAFR in a nonsmoking welder and a nonsmoking non-WF-exposed control subject was assessed by immunostaining samples from a study in which normal tissue was obtained at the time of a clinical biopsy for suspected cancer.¹⁶ Full details are provided in the [Methods](#) section in this article's Online Repository. Previous sampling and present analysis of human lung tissue was approved by an institutional review board for human studies.¹⁶

Statistical analysis

Statistical analysis was done with GraphPad Prism software (version 5.03; GraphPad Software, La Jolla, Calif). Data were obtained from at least 3 separate experiments performed at different times, with each data point representing the mean of at least 3 replicates, unless otherwise stated. Data

TABLE I. Composition of MS-WF

	Total weight of sample (%)
Aluminum	0.3
Barium	<0.1
Bismuth	<0.1
Calcium	8.9
Cobalt	<0.1
Chromium	<0.1
Copper	<0.1
Iron	12.4
Potassium	23.6
Lithium	0.4
Magnesium	5.3
Manganese	3.8
Molybdenum	<0.1
Sodium	2.6
Nickel	<0.1
Lead	<0.1
Silicon	2.1
Titanium	0.6
Vanadium	<0.1
Zinc	0.2
Fluoride ions	17.9
Chromium (VI)	<0.1

Each element is represented as a percentage of the total weight of the sample provided. The composition of MS-WF was determined by using inductively coupled plasma–atomic emission spectroscopy.

from *in vitro* airway epithelial experiments were analyzed by using either the *t* test or 1-way ANOVA and the Tukey multiple comparison test and are summarized as means (SEMs). Data from animal experiments are summarized by medians and analyzed either by using the Mann-Whitney test or Kruskal-Wallis test and the Dunn multiple comparison test. A *P* value of less than .05 was considered significant.

RESULTS

WF: OP

MS-WF contained iron, manganese, titanium, aluminum, and zinc (Table I). The OP of MW-WF for ascorbate and glutathione was increased compared with that of carbon black, and the total OP of MS-WF was increased compared with that of urban PM (Fig 1).

Pneumococcal adhesion and infection: Human airway cells

We first performed dose-response experiments with A549 and BEAS-2B cells to determine the optimal concentration of MS-WF that stimulated adhesion without causing cytotoxicity. MS-WF at concentrations between 200 and 400 $\mu\text{g}/\text{mL}$ for 2 hours increased pneumococcal adhesion and infection of both airway cell lines (Fig 2) without causing cytotoxicity, as assessed based on LDH release (see Fig E1 in this article's Online Repository at www.jacionline.org). A lower concentration of MS-WF (10 $\mu\text{g}/\text{mL}$) stimulated pneumococcal adhesion and infection, but this required extending culture duration to 24 hours (see Fig E2 in this article's Online Repository at www.jacionline.org). Thus we chose to expose cells to MS-WF for 2 hours at 275 $\mu\text{g}/\text{mL}$ (145 $\mu\text{g}/\text{cm}^2$) for A549 cells and 200 $\mu\text{g}/\text{mL}$ (105 $\mu\text{g}/\text{cm}^2$) for BEAS-2B cells. By adding antibiotics to kill the fraction of pneumococci adherent to cell surfaces, it was determined that MS-WF for 2 hours also increased the infective




FIG 1. The OP of MS-WF assessed based on their *in vitro* capacity to deplete antioxidants over 4 hours. Particle standards included in the assay are as follows: (1) low-OP carbon black (M120) and (2) high-OP urban air PM (NIST1648a). The OP of MS-WF (OP per microgram of PM) is given for ascorbate (**A**), glutathione (**B**), and total values (**C**). Data are from 3 experiments and presented as means (SEMs). Comparisons are performed by using 1-way ANOVA with the Tukey *post hoc* multiple comparison test. * $P < .05$ and *** $P < .001$.




FIG 2. Effect of 2 hours of exposure of human airway cells *in vitro* to MS-WF on pneumococcal adhesion and infection. Cells were infected with *S pneumoniae* for 2 hours at a multiplicity of infection of 100. **A**, A549 cells. **B**, BEAS-2B cells. Increased pneumococcal adhesion and infection are reflected by increased CFU values determined by means of quantitative bacterial culture. Data are from 3 to 4 separate experiments, each with 3 technical replicates, and presented as means (SEMs). Data are compared by using 1-way ANOVA and the Tukey *post hoc* multiple comparison test. * $P < .05$.

fraction of pneumococci (Fig 3). MS-WF did not directly stimulate pneumococcal growth (data not shown).

Pneumococcal infection: Mouse model

Intranasal instillation of a single 600- μ g dose of MS-WF in mice 24 hours before pneumococcal infection resulted in an increase in BALF and lung pneumococcal CFU values at 24 hours after pneumococcal infection (Fig 4). BALF and lung pneumococcal CFU values were also increased when MS-WF was administered as 6 separate 100- μ g doses once a day for 6 days (total, 600 μ g), followed by infection 24 hours after the last dose (see Fig E3 in this article's Online Repository at www.jacionline.org). In this model pneumococci were not isolated from the blood.

PAFR-dependent adhesion and infection: Human airway cells

A549 and BEAS-2B cell culture with MS-WF for 2 hours increased PAFR protein expression (Fig 5). The addition of CV-3988 to MS-WF-exposed cells reduced pneumococcal adhesion and infection of A549 and BEAS-2B cells and of human primary bronchial epithelial cells (Fig 6). Adding NAC at the same time as

MS-WF attenuated pneumococcal adhesion and infection of A549 and BEAS-2B cells (Fig 7).

PAFR-dependent infection: Mouse model

A single intranasal dose of 600 μ g of MS-WF increased lung PAFR mRNA expression at 24 hours (Fig 8). Pretreatment of MS-WF-exposed mice with CV-3988 1 hour before infection attenuated BALF CFU values. Pretreatment of MS-WF-exposed mice with CV-3988 did not reduce lung CFU values (Fig 9). In PBS-treated animals CV-3988 had no effect on either BALF or lung CFU values (data not shown).

PAFR: Stored samples

A 10-day course of 40 mg/m³ of aerosolized StS-WF for 3 hours per day increased mouse lung PAFR mRNA expression compared with that seen in air-exposed control subjects at both 4 hours and 28 days after the last dose (see Fig E4 in this article's Online Repository at www.jacionline.org).

Lung biopsy tissue was available from a single nonsmoking welder and a single nonsmoking control subject. Specific PAFR




FIG 3. Effect of exposure of human airway cells *in vitro* to MS-WF for 2 hours on the infective fraction of *S pneumoniae*. Cells were infected with *S pneumoniae* for 2 hours at a multiplicity of infection of 100. Pneumococci that were adherent to cell surfaces were first killed by antibiotics to assess the infective fraction. Intracellular bacteria that were protected from antibiotics were then recovered by means of cell lysis, and CFU values were assessed by means of quantitative culture. **A**, A549 cells cultured with 275 $\mu\text{g}/\text{mL}$ (145 $\mu\text{g}/\text{cm}^2$). **B**, BEAS-2B cells cultured with 200 $\mu\text{g}/\text{mL}$ (105 $\mu\text{g}/\text{cm}^2$). Data are from 3 separate experiments, with 3 technical replicates per experiment, and presented as means (SEMs). Data are compared by using *t* tests. **P* < .05.




FIG 4. Effect of exposure of mice to a single 600 μg intranasal dose of MS-WF on *S pneumoniae* CFU values. Mice were infected 24 hours after instillation of MS-WF, and CFU values were assessed by means of qualitative culture 24 hours after infection. **A**, BALF CFU values. **B**, Lung tissue CFU values. Dot plots are from 6 animals per group and compared by using the Mann-Whitney *U* test. Bars represent medians. ***P* < .01.

immunostaining of bronchial and alveolar epithelial cells was present in the nonsmoking welder. Less intense specific bronchial epithelial PAFR was present in the nonsmoking control subject (see Fig E5 in this article's Online Repository at www.jacionline.org).

DISCUSSION

In this study we sought to identify a mechanism for the hypersusceptibility of welders to bacterial pneumonia reported in epidemiologic studies.^{2,4,24} We focused on *S pneumoniae* because this bacterium is the most common cause of community-acquired pneumonia in adults.¹⁰ In addition, a review of all patients presenting with invasive pneumococcal disease (IPD) in Alberta (Canada) from 2000 to 2004 by Wong et al²⁵ reported a 2.7-fold greater incidence of IPD in welders; of the 18 welders with IPD, 17 had bacteremic pneumococcal pneumonia, 1 had meningitis, and 1 died of pneumococcal infection. Pneumococcal infection in welders remains a problem. For example, in April 2015, the Northern Ireland Health Protection Service investigated an outbreak of IPD in shipyard workers and identified WF exposure as a possible risk factor.²⁶




FIG 5. Effect of exposure of MS-WF on PAFR protein expression by human airway cells. Images were taken by using an epifluorescence microscope and analyzed with ImageJ software. A fluorescence intensity threshold was set to discount background fluorescence. The area of fluorescence (in square micrometers) was then measured for each image. **A**, A549 cells cultured with MS-WF (275 $\mu\text{g}/\text{mL}$) for 2 hours. **B**, BEAS-2B cells cultured with MS-WF (200 $\mu\text{g}/\text{mL}$) for 2 hours. Data are from 3 to 4 separate experiments, with 3 replicates per experiment. Control PAFR expression in separate experiments is highly variable, and data are therefore compared by using paired *t* tests. **P* < .05 versus control subjects.

In the present study we found that intranasal instillation of MS-WF in mice, followed by infection with *S pneumoniae*, resulted in a 50- to 175-fold increase in airway and lung CFU values.

We also found that MS-WF-induced hypersusceptibility to pneumococcal infection is mediated in part by PAFR (a host receptor used by pneumococci to adhere to and infect lower airway cells¹³) because MS-WF increased mouse lung PAFR mRNA expression and that treatment of mice with the PAFR blocker CV-3988 before pneumococcal infection significantly reduced lower airway bacterial load. Additional evidence for a role of PAFR was provided by *in vitro* experiments. First, MS-WF stimulated PAFR-dependent adhesion and infection of human lower airway cells. Second, CV-3988 attenuated MS-WF-stimulated pneumococcal adhesion and infection of human airway cell line cells and primary bronchial epithelial cells. Pneumococcal adhesion and infection stimulated by MS-WF is likely to be mediated by cellular oxidative stress because this is blocked by the antioxidant NAC. Indeed, these data are compatible with previous reports of induction of cellular oxidative stress by WF²⁷ and the capacity of NAC to attenuate pneumococcal adhesion and infection stimulated by fossil-fuel PM.¹⁴ Furthermore, increased glutathione peroxidase and total antioxidants in the serum of active welders provides evidence that WF induce oxidative stress *in vivo*.²⁸

To date, the role of PAFR in mediating vulnerability to pneumococcal pneumonia in human subjects is not fully defined.²⁹ However, this role is well established in animal models. For example, reduced PAFR expression by lower airway epithelial cells decreases mortality from pneumococcal infection in mice.³⁰ Conversely, increased airway epithelial PAFR causes hypersusceptibility of mice to pneumococcal infection.³¹ Indirect evidence that airway PAFR is important in human subjects is provided by our previous observation that bronchial epithelial PAFR expression is increased in smokers.¹⁵ In the present study PAFR was more strongly expressed by lower airway epithelial cell counts in the nonsmoking welder compared with the nonsmoking, non-WF-exposed control subject. To determine whether epithelial PAFR expression is increased in welders requires further lung biopsy samples from nonsmoking welders and nonsmoking control subjects, but to date, these have not been obtained.




FIG 9. Effect of intravenous treatment of mice with the PAFR blocker CV-3988 (5 mg/kg) administered 1 hour before infection with *S pneumoniae* in animals exposed to a single 600 µg intranasal dose of MS-WF. **A**, BALF pneumococcal CFU values. **B**, Lung pneumococcal CFU values. Data are representative of 2 separate experiments and compared by using the Kruskal-Wallis test and Dunn multiple comparison test. Bars represent medians. **P* < .05, ***P* < .01, and ****P* < .001.

infection, PAFR-independent mechanisms contribute to the development of pneumococcal infection in the lung tissue compartment.

In summary, we found that MS-WF increases PAFR-dependent pneumococcal adhesion and infection of human lower airway cells *in vitro* and pneumococcal airway infection in mice. This study suggests a mechanism for the increased vulnerability of welders to pneumococcal pneumonia reported in epidemiologic studies. Therefore these data provide biological plausibility for the UK Health and Safety Executive Guideline that the 23-valent pneumococcal polysaccharide vaccine “should be considered for people whose work exposes them to frequent or continuous exposure to metal fume (e.g. welders), taking into account the exposure control measures in place.”³⁴

We thank Professor David Coggon for his advice in developing this study and Esmie Purdie for performing the oxidative stress experiments.

Key messages

- Exposure of human lower airway epithelial cells to WF *in vitro* results in hypersusceptibility to platelet-activating factor-dependent pneumococcal adhesion and infection.
- Exposure of mice to WF results in hypersusceptibility to pneumococcal airway infection.
- The increased risk of pneumococcal pneumonia in welders reported in epidemiologic studies is biologically plausible.

REFERENCES

1. Registrar General. Decennial Supplement England and Wales 1971: Occupational Mortality Tables. London: HMSO; 1971.
2. Palmer KT, Cullinan P, Rice S, Brown T, Coggon D. Mortality from infectious pneumonia in metal workers: a comparison with deaths from asthma in occupations exposed to respiratory sensitizers. *Thorax* 2009;64:983-6.
3. Palmer KT, Poole J, Ayres JG, Mann J, Burge PS, Coggon D. Exposure to metal fume and infectious pneumonia. *Am J Epidemiol* 2003;157:227-33.
4. Toren K, Qvarfordt I, Bergdahl IA, Jarvholm B. Increased mortality from infectious pneumonia after occupational exposure to inorganic dust, metal fumes and chemicals. *Thorax* 2011;66:992-6.

5. Suri R, Mallia P, Martin JE, Footitt J, Zhu J, Trujillo-Torralbo MB, et al. Bronchial platelet-activating factor receptor in chronic obstructive pulmonary disease. *Respir Med* 2014;108:898-904.
6. Koh DH, Kim JI, Kim KH, Yoo SW, Korea Welders Cohort Group. Welding fume exposure and chronic obstructive pulmonary disease in welders. *Occup Med (Lond)* 2015;65:72-7.
7. Antonini JM, Roberts JR, Stone S, Chen BT, Schwegler-Berry D, Frazer DG. Short-term inhalation exposure to mild steel welding fume had no effect on lung inflammation and injury but did alter defense responses to bacteria in rats. *Inhal Toxicol* 2009;21:182-92.
8. Antonini JM, Stone S, Roberts JR, Chen B, Schwegler-Berry D, Afshari AA, et al. Effect of short-term stainless steel welding fume inhalation exposure on lung inflammation, injury, and defense responses in rats. *Toxicol Appl Pharmacol* 2007;223:234-45.
9. Antonini JM, Taylor MD, Millecchia L, Bebout AR, Roberts JR. Suppression in lung defense responses after bacterial infection in rats pretreated with different welding fumes. *Toxicol Appl Pharmacol* 2004;200:206-18.
10. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. *Lancet* 2009;374:1543-56.
11. Swords WE, Buscher BA, Ver Steeg Ii K, Preston A, Nichols WA, Weiser JN, et al. Non-typeable *Haemophilus influenzae* adhere to and invade human bronchial epithelial cells via an interaction of lipooligosaccharide with the PAF receptor. *Mol Microbiol* 2000;37:13-27.
12. Smani Y, Docobo-Perez F, Lopez-Rojas R, Dominguez-Herrera J, Ibanez-Martinez J, Pachon J. Platelet-activating factor receptor initiates contact of *Acinetobacter baumannii* expressing phosphorylcholine with host cells. *J Biol Chem* 2012;287:26901-10.
13. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI. *Streptococcus pneumoniae* anchor to activated human cells by the receptor for platelet-activating factor. *Nature* 1995;377:435-8.
14. Mushtaq N, Ezzati M, Hall L, Dickson I, Kirwan M, Png KM, et al. Adhesion of *Streptococcus pneumoniae* to human airway epithelial cells exposed to urban particulate matter. *J Allergy Clin Immunol* 2011;127:1236-42.e2.
15. Grigg J, Walters H, Sohal SS, Wood-Baker R, Reid DW, Xu CB, et al. Cigarette smoke and platelet-activating factor receptor dependent adhesion of *Streptococcus pneumoniae* to lower airway cells. *Thorax* 2012;67:908-13.
16. Andujar P, Simon-Deckers A, Galateau-Salle F, Fayard B, Beaune G, Clin B, et al. Role of metal oxide nanoparticles in histopathological changes observed in the lung of welders. *Part Fibre Toxicol* 2014;11:23.
17. McNeilly JD, Heal MR, Beverland IJ, Howe A, Gibson MD, Hibbs LR, et al. Soluble transition metals cause the pro-inflammatory effects of welding fumes *in vitro*. *Toxicol Appl Pharmacol* 2004;196:95-107.
18. Zimmer AT, Baron PA, Biswas P. The influence of operating parameters on number-weighted aerosol size distribution generated from a gas metal arc welding process. *J Aerosol Sci* 2002;33:519-31.
19. Kelly F, Anderson HR, Armstrong B, Atkinson R, Barratt B, Beevers S, et al. The impact of the congestion charging scheme on air quality in London. Part 2. Analysis of the oxidative potential of particulate matter. *Res Rep Health Eff Inst* 2011;155:73-144.

20. Godri KJ, Green DC, Fuller GW, Dall'Osto M, Beddows DC, Kelly FJ, et al. Particulate oxidative burden associated with firework activity. *Environ Sci Technol* 2010;44:8295-301.
21. Robertson DN, Smith GM. CV3988 inhibits in vivo platelet aggregation induced by PAF-acether and collagen. *Eur J Pharmacol* 1986;123:91-7.
22. Messier EM, Day BJ, Bahmed K, Kleeberger SR, Tuder RM, Bowler RP, et al. N-acetylcysteine protects murine alveolar type II cells from cigarette smoke injury in a nuclear erythroid 2-related factor-2-independent manner. *Am J Respir Cell Mol Biol* 2013;48:559-67.
23. Antonini JM, Afshari AA, Stone S, Chen B, Schwegler-Berry D, Fletcher WG, et al. Design, construction, and characterization of a novel robotic welding fume generator and inhalation exposure system for laboratory animals. *J Occup Environ Hyg* 2006;3:194-203, quiz D145.
24. Coggon D, Inskip H, Winter P, Pannett B. Lobar pneumonia: an occupational disease in welders. *Lancet* 1994;344:41-3.
25. Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ, Group S. Welders are at increased risk for invasive pneumococcal disease. *Int J Infect Dis* 2010;14:e796-9.
26. Patterson L, Irvine N, Wilson A, Doherty L, Loughrey A, Jessop L. Outbreak of invasive pneumococcal disease at a Belfast shipyard in men exposed to welding fumes, Northern Ireland, April-May 2015: preliminary report. *Eurosurveillance* 2015;20(21).
27. Badding MA, Fix NR, Antonini JM, Leonard SS. A comparison of cytotoxicity and oxidative stress from welding fumes generated with a new nickel-, copper-based consumable versus mild and stainless steel-based welding in RAW 264.7 mouse macrophages. *PLoS One* 2014;9:e101310.
28. Han SG, Kim Y, Kashon ML, Pack DL, Castranova V, Vallyathan V. Correlates of oxidative stress and free-radical activity in serum from asymptomatic shipyard welders. *Am J Respir Crit Care Med* 2005;172:1541-8.
29. Iovino F, Brouwer MC, van de Beek D, Molema G, Bijlsma JJ. Signalling or binding: the role of the platelet-activating factor receptor in invasive pneumococcal disease. *Cell Microbiol* 2013;15:870-81.
30. Duitman J, Schouten M, Groot AP, Borensztajn KS, Daalhuisen JB, Florquin S, et al. CCAAT/enhancer-binding protein delta facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner. *Proc Natl Acad Sci U S A* 2012;109:9113-8.
31. Miller ML, Gao G, Pestina T, Persons D, Tuomanen E. Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor. *J Infect Dis* 2007;195:581-4.
32. Phalen RF, Oldham MJ, Nel AE. Tracheobronchial particle dose considerations for in vitro toxicology studies. *Toxicol Sci* 2006;92:126-32.
33. Kim JY, Chen JC, Boyce PD, Christiani DC. Exposure to welding fumes is associated with acute systemic inflammatory responses. *Occup Environ Med* 2005;62:157-63.
34. Health and Safety Executive (HSE). Pneumonia vaccination for employees exposed to welding and metal fume. 2014. Available at: <http://www.hse.gov.uk/pubns/eis44.pdf>, 2014. Accessed May 29, 2015.

METHODS

PAFR expression: Stored mouse lung tissue

Mice inhaled StS-WF composed of (weight percentage) iron (57%), chromium (20%), manganese (13%), nickel (8%), and copper (0.2%) with trace amounts of silicon, aluminum, and vanadium. The particle diameters ranged from ultrafine (0.01-0.1 μm) to coarse (1.0-10 μm), with the majority of particles in the fine size range (0.1-1.0 μm). The mass median aerodynamic diameter was 0.255 μm , with a geometric SD of 1.35. RNA from mice exposed to aerosolized StS-WF was isolated from whole-lung homogenates by using TRIzol (Invitrogen) and then cleaned according to the manufacturer's instructions with an RNeasy Mini Kit (Qiagen). A 2 μL aliquot of each RNA sample was quantified by using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, Del). Briefly, RT-qPCR reactions were carried out by using StepOne (Applied Biosystems, Foster City, Calif) with predesigned Assays-on-Demand TaqMan probes and primers (Applied Biosystems). By using 96-well plates, 1 μg of total RNA was reverse transcribed with random hexamers (Applied Biosystems) and Superscript III (Invitrogen). Hypoxanthine-guanine phosphoribosyltransferase was used as the reference gene. Relative gene expression was calculated by using the

comparative cycle threshold ($\Delta\Delta C_T$) method. All procedures and protocols were approved by the Animal Care and Use Committee of the National Institute for Occupational Safety and Health.

PAFR expression: Stored human lung tissue

PAFR antigen retrieval in human lung biopsy tissue was carried out on 3- μm paraffin wax-embedded sections dried overnight at 60°C. Slides were placed in an EDTA buffer of pH 8.1 and microwaved at full power for 35 minutes. Slides were then transferred to a DAKO autostainer (DAKO, Glostrup, Denmark), where they were treated with a 3% peroxidase block followed by using the R.T.U Vectastain Kit (PK-7200; Vector Laboratories, Burlingame, Calif), according to the manufacturer's recommendations. The working dilution of the human anti-PAFR mAb CAY160600 (Cayman Chemical) was used at 1:100, and the incubation time was 40 minutes. The signal was visualized by using DAKO DAB+ Chromogen Solution (K3468) applied for 5 minutes. A Gills hematoxylin nuclei counterstain was used for 2 minutes. A negative control using tonsil tissue without the anti-PAFR antibody showed no nonspecific diaminobenzidine signal.




FIG E1. LDH release from A549 cells exposed to 2 hours of MS-WF (**A**) and BEAS-2B cells exposed to 2 hours of MS-WF (**B**). Data are from a single experiment, with 3 technical replicates. The positive control is assessed after total cell lysis by using distilled water. MS-WF at concentrations of 400 µg/mL or less do not cause cytotoxicity in this assay.




FIG E2. Effect of exposure of airway cells to 10 $\mu\text{g/mL}$ ($5 \mu\text{g/cm}^2$) MS-WF *in vitro* for 24 hours on the adhesion of *S pneumoniae* to A549 cells (**A**) and BEAS-2B cells (**B**). Increased CFU values determined by using quantitative culture reflect increased pneumococcal adherence. Data are from 3 separate experiments, described as means (SEMs), and compared by using the *t* test. ***P* < .01 versus medium control.




FIG E3. Effect of exposure of mice to 600 μ g of intranasal MS-WF administered as 100- μ g doses once a day for 6 days on *S pneumoniae* CFU values in BALF (**A**) and lung tissue (**B**). Mice were infected 24 hours after instillation of the last dose of MS-WF, and CFU values were assessed by means of qualitative culture. Data are from 6 animals per group and compared by using the Mann-Whitney *U* test. Bars represent medians. ** $P < .01$.




FIG E4. Effect of aerosolized StS-WF on mouse lung PAFR mRNA expression. PAFR mRNA expression was assessed by using real-time quantitative PCR with hypoxanthine-guanine phosphoribosyltransferase as the reference gene. Relative gene expression was calculated by using the $\Delta\Delta$ cycle threshold method. **A**, Four hours after a 10-day course of aerosolized StS-WF (40 mg/m^3) for 3 hours. **B**, Twenty-eight days after a 10-day course of 3 hours per day of aerosolized StS-WF (40 mg/m^3). Dot plots are from 4 mice per group. Data are compared by using the Mann-Whitney test. Bars represent medians. $*P < .05$.




FIG E5. PAFR immunostaining in the human lung. A biopsy specimen of normal tissue was obtained at the time of biopsy for malignancy. **A**, Lung tissue from a nonsmoking welder stained with an isotypic control mAb. There is no specific (*brown*) staining of epithelial cells. **B**, Lung tissue from a nonsmoking welder stained with a PAFR mAb. There is marked specific staining of bronchial epithelial cells and some specific staining of alveolar epithelial cells. **C**, Lung tissue from a nonsmoking, non-WF-exposed control subject stained with an isotypic control mAb. **D**, Lung tissue from a nonsmoking, non-WF-exposed control subject stained with a PAFR mAb. There is specific PAFR staining of bronchial epithelial cells (*brown*).




FIG E6. Effect of the PAFR blocker CV-3988 (20 $\mu\text{mol/L}$) on adhesion of *S pneumoniae* to airway cells after 2 hours of exposure to StS-WF. StS-WF (chromium, 4.1%; iron, 3.9%; manganese, 2.7%; and titanium, 1.5%) were generated as described in the Methods section by using E308L manual metal arc welding electrodes. Increased CFU values determined by using quantitative culture reflect increased pneumococcal adhesion and infection. **A**, A549 cells plus 275 $\mu\text{g/mL}$ StS-WF. **B**, BEAS-2B cells plus 200 $\mu\text{g/mL}$ StS-WF. StS-WF stimulates pneumococcal adhesion, and this is attenuated by CV-3988. Data are from 4 separate experiments, with 3 replicates per experiment. Data are described as means (SEMs) and compared by using 1-way ANOVA and the Tukey multiple comparison test. * $P < .05$, ** $P < .01$, and *** $P < .001$.